Phase 2a rheumatoid arthris ("RA") data not only achieved the primary endpoint of safety and tolerability, but also stascally significant improvement in the ACR20 and encouraging signals in other RA disease measures; despite being insufficiently powered. 60 paents with inadequate response to methotrexate and or TNFα inhibitors were included in the trial. Adverse events ("AE") were mild and dose dependent. While there were some AE-related paent drop out, recent data in ulcerave colis ("U ....
23 Jun 2021
RA Phase 2a opens door to $90bn market
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
RA Phase 2a opens door to $90bn market
Abivax SA (0RA9:LON) | 0 0 0.5% | Mkt Cap: 83.0m
- Published:
23 Jun 2021 -
Author:
Chris Redhead -
Pages:
5
Phase 2a rheumatoid arthris ("RA") data not only achieved the primary endpoint of safety and tolerability, but also stascally significant improvement in the ACR20 and encouraging signals in other RA disease measures; despite being insufficiently powered. 60 paents with inadequate response to methotrexate and or TNFα inhibitors were included in the trial. Adverse events ("AE") were mild and dose dependent. While there were some AE-related paent drop out, recent data in ulcerave colis ("U ....